China Health Holding Announces Pharmaceutical Development Plans Seeking FDA Approval for Promising Traditional Herbal Medicines.BEIJING -- China Health Holding, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : CHHH), a developer and marketer of traditional Chinese-based herbal supplement products, announced today plans to seek FDA/Health Canada approval for its promising Traditional Herbal Medicines through its 100% owned subsidary China Health World Pharmaceutical Corporation. The Company plans to pursue for Molecular Laboratory Analysis compliant with Federal Guidelines (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and Health Canada Health Canada (French: Santé Canada) is the department of the government of Canada with responsibility for national public health. Health Canada's goal is to improve Canadian life by improving Canadian longevity, lifestyle and use of public healthcare. ) for its promising Traditional Herbal Medicines. The Company plans to file an Investigational New Drug Application (IND) for its traditional herbal medicines in order to replicate the success in the North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. market that these products have had in China. In connection with the IND, the Company plans to perform a proof of concept trial on about 20 patients in order to develop a protocol and trial design for the study. The Company also expects to form a Global Medical Scientific Advisory Board, comprised of leading members of the academic and scientific communities. China Health Holding also plans to file worldwide patent applications in order to protect the Company's intellectual property for these promising products. "The products in our portfolio represent the best in Traditional Herbal Medicines," said Julianna Lu, President of China Health Holding. "They have already had success in China in curing certain cancers, diabetes mellitus diabetes mellitus Disorder of insufficient production of or reduced sensitivity to insulin. Insulin, synthesized in the islets of Langerhans (see Langerhans, islets of), is necessary to metabolize glucose. In diabetes, blood sugar levels increase (hyperglycemia). , cardio-vascular and cerebral-vascular system dysfunctions, neurological disorders, and immunological dysfunctions (HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. ), incontinence and other large-market opportunities. We look forward to bringing them to North America so that our customers can experience the benefits of eastern-style healthcare." About China Health Holding, Inc. China Health Holding, Inc., incorporated in 2002, is a developer and marketer of traditional Chinese herbal supplement products. The Company's products also include dietary food supplements that are helpful in strengthening the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. and cardio-cerebral vascular function as well as promoting overall physical and mental health. The Company plans to introduce a line of 100% natural skin care and cosmetic products as well as to develop new pharmaceutical products based on its unique knowledge of traditional Chinese medical practice. Please visit China Health Holding, Inc.'s website www.chinahealthholding.com for Company Profile details. This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. China Health Holding refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company, which can be viewed on the SEC's website at www.sec.gov. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion